# Elegen

> Elegen is a Menlo Park biotechnology company that manufactures long, complex synthetic DNA without using bacterial cells for its core cloning step. Its ENFINIA products serve researchers and drug developers working in mRNA, cell and gene therapy, protein expression, genome editing and synthetic biology, with NGS-verified linear DNA up to 7 kb shipped in as few as six business days and list pricing from $0.07 per base pair.

- **Founded:** 2017
- **Headquarters:** Menlo Park, United States
- **Founders:** Matthew Hill (Founder and CEO)
- **Products:** ENFINIA Linear DNA, ENFINIA Plasmid DNA, ENFINIA IVT Ready DNA, GEN II Cell-Free DNA Production Platform
- **Notable:** Launched ENFINIA Linear DNA commercially in 2023 with lengths up to 7 kb., Reported a median synthesis error rate as low as 1 in 70,000 base pairs for ENFINIA Linear DNA., Raised a $35 million Series B led by Triatomic Capital in May 2024.

## Products & services

- **ENFINIA Linear DNA** — Cell-free, double-stranded linear DNA from 300 bp to 7 kb, NGS-verified, with a median error rate as low as 1 in 70,000 bp and shipment in 6-8 business days. Standard-complexity pricing begins at $100 per sequence below 1 kb or $0.07 per bp from 1-7 kb.
- **ENFINIA Plasmid DNA** — NGS-verified plasmids up to 19 kb containing inserts up to 15 kb, built from cell-free ENFINIA linear DNA and delivered in as few as 10 business days. Standard-complexity pricing begins at $0.12 per bp for inserts of 1 kb or longer.
- **ENFINIA IVT Ready DNA** — Linear DNA templates up to 5.5 kb with encoded continuous or segmented poly(A) tails for direct in-vitro transcription, intended for mRNA vaccine, therapeutic and genome-editing workflows.
- **GEN II Cell-Free DNA Production Platform** — An automated production system combining directed split-pool microfluidic oligonucleotide synthesis, DNA assembly and cell-free cloning; it supports all three ENFINIA product lines.

## Achievements

- Launched ENFINIA Linear DNA commercially in 2023 with lengths up to 7 kb.
- Reported a median synthesis error rate as low as 1 in 70,000 base pairs for ENFINIA Linear DNA.
- Raised a $35 million Series B led by Triatomic Capital in May 2024.
- Was ranked No. 2 in Fast Company's 2024 Small but Mighty category and appeared again in the category in 2025.
- Expanded the portfolio to plasmids with inserts up to 15 kb and IVT-ready templates up to 5.5 kb in 2025.
- Deployed GEN II and cut standard linear DNA list pricing to $0.07 per base pair in 2026.
- Validated greater than 92% success in an internal plasmid-production study covering long and complex sequences.

## Latest updates

- **2026-01** — Elegen lowered ENFINIA list prices to as little as $0.07 per bp for linear DNA, $0.12 per bp for plasmid inserts and $0.11 per bp for IVT-ready DNA, crediting the GEN II platform.
- **2026-02** — The company presented a technical webinar on the architecture and performance of GEN II; the platform is now described as generally available.
- **2025-10** — Elegen opened early access to GEN II, combining a directed split-pool microfluidic synthesizer with automated cell-free cloning.
- **2025-09** — Elegen commercially launched ENFINIA IVT Ready DNA for mRNA production.
- **2025-07** — Elegen and Nutcracker Therapeutics began a pilot for fully cell-free personalized cancer-therapy manufacturing.

## Links

- Website: https://elegenbio.com/
- LinkedIn: https://www.linkedin.com/company/elegenbio/
- Twitter/X: https://x.com/ElegenBio
- YouTube: https://youtu.be/bg9PT132QL0

---

Profile page: https://yespress.io/elegen
Published by YesPress — https://yespress.io
Last updated: 2026-09-26